Aravive Inc (ARAV) Stock Price, Forecast & Analysis
NASDAQ:ARAV • US03890D1081
ARAV Key Statistics, Chart & Performance
The current stock price of ARAV is 0.0401 USD. In the past month the price decreased by -68.84%. In the past year, price decreased by -97.76%.
ARAV Technical Analysis
ARAV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ARAV. ARAV scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ARAV Financial Highlights
Over the last trailing twelve months ARAV reported a non-GAAP Earnings per Share(EPS) of -0.96. The EPS increased by 59.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -306.54% | ||
| ROE | -2344.12% | ||
| Debt/Equity | 0 |
ARAV Forecast & Estimates
6 analysts have analysed ARAV and the average price target is 0.26 USD. This implies a price increase of 535.91% is expected in the next year compared to the current price of 0.0401.
For the next year, analysts expect an EPS growth of 90.73% and a revenue growth -38.62% for ARAV
ARAV Ownership
ARAV Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 401.054B | ||
| AMGN | AMGEN INC | 16.69 | 206.954B | ||
| GILD | GILEAD SCIENCES INC | 16.12 | 182.529B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.42 | 122.559B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.88 | 82.914B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.81 | 43.248B | ||
| INSM | INSMED INC | N/A | 31.694B | ||
| NTRA | NATERA INC | N/A | 29.474B | ||
| BIIB | BIOGEN INC | 12.37 | 27.992B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.91 | 23.041B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ARAV
Company Profile
Aravive, Inc. operates as a clinical stage biotechnology company, which engages in the development of transformative treatments designed to halt the progression of life threatening disease, including cancer and fibrosis. The company is headquartered in Houston, Texas and currently employs 23 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The firm's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Company Info
Aravive Inc
River Oaks Tower, 3730 Kirby Drive, Suite 1200
Houston TEXAS 77098 US
CEO: Gail McIntyre
Employees: 23
Phone: 19363551910
Aravive Inc / ARAV FAQ
What does Aravive Inc do?
Aravive, Inc. operates as a clinical stage biotechnology company, which engages in the development of transformative treatments designed to halt the progression of life threatening disease, including cancer and fibrosis. The company is headquartered in Houston, Texas and currently employs 23 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The firm's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Can you provide the latest stock price for Aravive Inc?
The current stock price of ARAV is 0.0401 USD. The price decreased by -13.39% in the last trading session.
Does ARAV stock pay dividends?
ARAV does not pay a dividend.
How is the ChartMill rating for Aravive Inc?
ARAV has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for Aravive Inc?
Aravive Inc (ARAV) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for Aravive Inc?
Aravive Inc (ARAV) currently has 23 employees.
What is Aravive Inc worth?
Aravive Inc (ARAV) has a market capitalization of 2.95M USD. This makes ARAV a Nano Cap stock.